Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 9/20 | 0.48 |
| ▸ | GLP1R | P43220 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | STAT6 | P42226 | 3/20 | 0.41 |
| ▸ | CD38 | P28907 | 1/20 | 0.41 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.41 |
| ▸ | STK17B | O94768 | 1/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.40 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3189750 | 0.91 | HDAC3 (0.51) | SCDGLP1RSTAT6STK17ASTK17B | |
| SCHEMBL3192454 | 0.91 | HDAC3 (0.41) | SCDGLP1RSTAT6STK17ASTK17B | |
| SCHEMBL3186194 | 0.88 | VNN1 (0.46) | STK17ASTK17BMAPK8MAPK9 | |
| SCHEMBL3190029 | 0.86 | HDAC3 (0.49) | SCDSTAT6CD38RPS6KB1 | |
| SCHEMBL3171713 | 0.86 | STK17B (0.47) | SCDTSHRSTAT6CD38STK17A | |
| SCHEMBL3191032 | 0.85 | VNN1 (0.43) | MAPK8MAPK9AURKARPS6KB1 | |
| SCHEMBL3182040 | 0.85 | SCD (0.47) | SCDSTAT6CD38STK17ASTK17B | |
| SCHEMBL1917348 | 0.85 | PTK2 (0.48) | SCDTSHRSTK17A | |
| SCHEMBL3179929 | 0.84 | IKBKB (0.44) | STAT6STK17AMAPK8MAPK9 | |
| SCHEMBL3187807 | 0.83 | SIRT5 (0.49) | TSHRSTAT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | GILEAD PALO ALTO, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7662819-B2 | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD PALO ALTO, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662819-B2 | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD PALO ALTO, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-7662819-B2 | Pteridinone derivatives for use as stearoyl CoA desaturase inhibitors | GILEAD PALO ALTO, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| EP-2131844-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV Therapeutics Inc. (US) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008123891-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | CV THERAPEUTICS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | LIGAND PHARMACEUTICALS INCORPORATED | 2008-10-09 | — | — | US | disclosed |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | LIGAND PHARMACEUTICALS INCORPORATED | 2008-10-09 | — | — | US | disclosed |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | LIGAND PHARMACEUTICALS INCORPORATED | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113463-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, COASY | SCD 1/4885GLP1R 1110/4885TSHR 4229/4885 |
| US-20080249100-A1 | PTERIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS | SCD, SCD5, COASY | SCD 1/4885GLP1R 1110/4885TSHR 4229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.